BioSpace News Archive

BIOREM Inc. (TSXV: BRM) (“Biorem” or “the Company”) today announced its results for the three and twelve-month periods ended December 31, 2021.

Everest Medicines announced its financial results for full year ended December 31, 2021, along with a corporate progress update.

Samsung Biologics, the world’s leading contract development and manufacturing organization, hosted its 11th Annual General Meeting of Shareholders.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL® capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia from the Japanese Ministry of Health, Labour and Welfare on March 28, 2022.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a 2 mg dose of Ozempic® (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.

Envista announced the 510 Food and Drug Administration clearance of its Assisted Intelligence mandibular nerve tracing feature in its image acquisition and diagnostic software platform DTX Studio Clinic.

Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), today announced clinical and regulatory updates on its lead program, CLN-081.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced two key appointments to its new management structure.

Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021.